In addition, anticholinergic medications are associated with a risk of cognitive decline with long-term use, and this relationship has been shown to be dose-dependent.4 Although causality has not been established, there is a plausible mechanism for this association with dementia which can further worsen overall health and well-being. It is important to counsel patients that if they are not getting satisfactory relief of OAB symptoms on medications, they should seek alternative treatment.
Overall, third line therapy should be used in a larger proportion of patients with refractory OAB. At this time we believe that the primary barrier to progression to third line therapy is lack of knowledge about these treatments amongst both physicians and patients. By promoting awareness and knowledge about third line therapy we can improve the quality and efficiency of care for OAB patients.
Written by: Dena Moskowitz and Kathleen C Kobashi
Read the Abstract
1 Gormley, E.A., D.J. Lightner, K.L. Burgio, et al., Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol, 2012. 188(6 Suppl): p. 2455-63.
2 Anger, J.T., A.P. Cameron, R. Madison, et al., The effect of sacral neuromodulation on anticholinergic use and expenditures in a privately insured population. Neuromodulation, 2014. 17(1): p. 72-4; discussion 74.
3 Autiero, S.W., N. Hallas, C.D. Betts, et al., The cost-effectiveness of sacral nerve stimulation (SNS) for the treatment of idiopathic medically refractory overactive bladder (wet) in the UK. BJU Int, 2015. 116(6): p. 945-54.
4 Gray, S.L., M.L. Anderson, S. Dublin, et al., Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med, 2015. 175(3): p. 401-7.